November 04, 2025

Get In Touch

IV Diltiazem Tops Metoprolol For Treating Patients Of Atrial Fibrillation With Rapid Ventricular Rate: Study

Study on Intravenous Diltiazem vs. Metoprolol

Study on Intravenous Diltiazem vs. Metoprolol

In China, intravenous diltiazem and metoprolol are commonly used for treating atrial fibrillation (AF) with rapid ventricular rate (RVR) in the emergency department (ED). However, the advantages and disadvantages of these drugs cannot be verified. A recent study in the American Journal of Emergency Medicine found that IV diltiazem versus metoprolol has higher efficacy, lower ventricular rate, shorter average onset time, less impact on blood pressure, and no increase in adverse events.

In the study, published in The American Journal of Emergency Medicine, Qingsu Lan, The First Clinical Medical College, Lanzhou University, Lanzhou, China, and colleagues aimed to assess the efficacy and safety of intravenous diltiazem versus metoprolol for AF with RVR.

For this purpose, the researchers systematically searched the online databases. Meta-analysis was performed using weighted mean difference (WMD), relative risk (RR), and 95% confidence interval (CI). Using Review Manager 5.4.1., the researcher performed statistical analysis.

The meta-analysis included seventeen studies involving 1214 patients in nine randomized controlled trials (RCTs) and eight cohort studies. 643 patients were included in the intravenous diltiazem group and 571 patients in the intravenous metoprolol group.

The results of the meta-analysis showed that compared with intravenous metoprolol, intravenous diltiazem was found to have:

  • Higher efficacy (RR = 1.11)
  • Shorter average onset time (RR = −1.13)
  • Less impact on systolic blood pressure (WMD = 3.76)
  • Lower ventricular rate (RR = −9.48)
  • Diastolic blood pressure (WMD = −1.20)
  • No significant difference in adverse events (RR = 0.80) was found between intravenous diltiazem and metoprolol

"Intravenous diltiazem has higher efficacy, shorter average onset time, lower ventricular rate, less impact on blood pressure, and with no increase in adverse events compared to intravenous metoprolol," wrote the researchers.

Reference

The study titled, "Intravenous diltiazem versus metoprolol for atrial fibrillation with rapid ventricular rate: A meta-analysis," is published in The American Journal of Emergency Medicine.

DOI: https://www.sciencedirect.com/science/article/abs/pii/S0735675721008883

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!